SOAT1 and digestive system disorder: Notably, the JAK-STAT pathway showed strong potential for drug repurposing, with adalimumab targeting tumor necrosis factor and ustekinumab targeting interleukin-12 subunit beta already being used to treat both skin and GIT diseases.